加拿大儿科中心管理的新冠免疫接种后心脏不良事件的短期和长期结局
该单中心回顾性病例系列纳入2021年5月至2022年5月诊断的17例辉瑞/BioNTech mRNA新冠疫苗接种后心脏不良事件儿科患者,均为男性,平均年龄16岁,多数表现为心肌心包炎,全部经非甾体抗炎药治疗后好转且无复发,随访至12个月时临床恢复,但部分报告生活质量和心理健康受负面影响及新发疫苗犹豫。
要点
- 17例心脏不良事件均为男性,平均年龄16岁(范围12-17岁),多数发生于第2剂(12/17)或第3剂(4/17)后。
- 15/17例表现为心肌心包炎,全部经非甾体抗炎药治疗后迅速好转,无复发。
- 5例报告生活质量和心理健康受负面影响,其中2例导致对新发疫苗犹豫,不仅对新冠疫苗,也对其他常规疫苗。
核心结论
- 心脏不良事件后12个月,所有患者心肌心包炎临床恢复,但部分报告生活质量和心理健康受负面影响,包括新发疫苗犹豫。
- 作者认为这凸显了对心脏不良事件及时系统评估的重要性,以及为经历不良事件的个体提供支持、随访和疫苗咨询的必要性。
研究设计与样本
- 单中心回顾性病例系列,纳入2021年5月至2022年5月诊断的辉瑞/BioNTech mRNA新冠疫苗接种后心脏不良事件儿科患者,按标准化方案管理,随访信息至诊断后12个月。
- 所有病例均为男性(N=17),平均年龄16岁(范围12-17岁)。
- 估算渥太华居民心脏不良事件发生率。
主要发现
- 多数病例发生于第2剂(12/17)或第3剂(4/17)疫苗接种后,主要表现为心肌心包炎(15/17)。
- 第1剂与第2剂疫苗(n=12)平均间隔38天(21-69天)。
- 所有患者经非甾体抗炎药治疗后迅速好转,无复发。
- 5例报告生活质量和心理健康受负面影响,其中2例导致新发疫苗犹豫,不仅对新冠疫苗,也对其他常规疫苗。
- 12至17岁男性第2剂后心脏不良事件发生率为每10万剂12.01例(90%CI 5.98-21.68),第3剂后为每10万剂16.56例(90%CI 5.66-37.90)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous reports have described the clinical presentation of cardiac adverse events following immunization (AEFI) with COVID-19 vaccines but long-term outcome studies are limited, especially in the pediatric population. METHODS: This is a single center retrospective case series of pediatric patients with cardiac AEFI following the Pfizer/BioNTech mRNA COVID-19, diagnosed between May 2021 and May 2022, and managed following a standardized protocol. Follow up information is presented up to 12 months post diagnosis. The incidence rate of cardiac AEFI was estimated for Ottawa residents. RESULTS: All cases were male (N = 17) with an average age of 16 years (range = 12-17). The majority of cases occurred after the 2nd (12/17) or 3rd vaccine dose (4/17) and were manifested mostly as myopericarditis (15/17). Average interval between the 1st and 2nd vaccine (n = 12) doses was 38 days (21-69 days). All patients improved promptly on non-steroidal anti-inflammatory drugs without recurrence. Five patients reported negative impact on quality of life and mental health, including 2 cases that led to new vaccine hesitancy, not only to COVID-19 vaccine, but also to other routine vaccines. The rate of cardiac AEFI was estimated for residents of the city of Ottawa and found to be 12.01 cases (CI 90 5.98-21.68) per 100,000 doses following the 2nd dose and 16.56 cases (CI 90 5.66-37.90) per 100,000 doses following the 3rd dose for males aged 12 to 17 years. CONCLUSIONS: Twelve months following the AEFI, all patients clinically recovered from their myopericarditis, but some reported negative impact on quality of life and mental health, including new vaccine hesitancy. This highlights the importance for timely and systematic evaluation of AEFI and the need to provide support, follow up and vaccine counseling in individuals experiencing an AEFI.
引用
- Pham-Huy A, Bowes J, Russell K, et al. Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center. Vaccine. 2024. PMID: 39003104. doi:10.1016/j.vaccine.2024.06.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。